223 related articles for article (PubMed ID: 32636936)
1. Teprotumumab: a disease modifying treatment for graves' orbitopathy.
Ting M; Ezra DG
Thyroid Res; 2020; 13():12. PubMed ID: 32636936
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab: First Approval.
Markham A
Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.
Bocklud BE; Fakhre W; Murphy B; Maddox K; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2023 Aug; 15(8):e43878. PubMed ID: 37746376
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
9. Teprotumumab in thyroid eye disease.
Goldberg H; Malik AI
Saudi J Ophthalmol; 2024; 38(1):29-33. PubMed ID: 38628412
[TBL] [Abstract][Full Text] [Related]
10. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
Safo MB; Silkiss RZ
Am J Ophthalmol Case Rep; 2021 Jun; 22():101069. PubMed ID: 33817409
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
13. An Interesting Case of Euthyroid Graves' Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies.
Moeen Z; Aliuddin AM; Gray Wlazlo T; Majid H; Kolli S
Cureus; 2021 Oct; 13(10):e19015. PubMed ID: 34853745
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis.
Li H; Yang L; Song Y; Zhao X; Sun C; Zhang L; Zhao H; Pan Y
Acta Ophthalmol; 2022 Sep; 100(6):e1189-e1198. PubMed ID: 34918472
[TBL] [Abstract][Full Text] [Related]
15. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
16. Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.
Lee ACH; Kahaly GJ
Eur Thyroid J; 2020 Dec; 9(Suppl 1):17-30. PubMed ID: 33511082
[TBL] [Abstract][Full Text] [Related]
17. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis.
Fatani WA; Hamdan DM; Taher NO; Alsharef JF; Aldubi RM; Alwagdani AM; Alhothali TN; Khan ZU
Saudi J Ophthalmol; 2023; 37(2):137-148. PubMed ID: 37492211
[TBL] [Abstract][Full Text] [Related]
20. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
Singh G; Taylor B; Michalek S
Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
